Not a science guy. Undergrad/grad stats, yes.

The more the Illumina machine is fed (the more times that patient sample "events" occur), the stronger the chance of finding new "shared" neoantigens among the human population. Time reduction in any process helps reduce cost. You have it--the larger the library, the higher the value of the company.

Three elements of positive value exist in hunTR -- the higher the degree of accuracy within the process of interrogation ... the higher is the efficacy outcome;

the greater the count of shared neoantigens ... the more the cost of manufacturing is reduced and

the larger the library, the larger the addressable "patented" market grows, creating a revenue flow in licensing the patent and hunTR process to cancer clinics.

At the close of the Aldeveron video, the gene engineer being interviewed by Cooper stated that he hoped that the future of TCR-T would include storing all TCR-T designs, shared or not ... presumably just to have that first step in batching already done.